Brief: Affluent Medical H1 Operating Loss EUR 7.4 Mln
28/09/2023 16:56
Sept 28 (Reuters) - Affluent Medical SAS AFME.PA :
* H1 2023 RESULTS. MAJOR ADVANCES IN CLINICAL PROGRAMS.
EXTENSION
OF CASH HORIZON TO FEBRUARY 2024.
* EXTENSION OF FINANCIAL VISIBILITY UNTIL FEBRUARY 2024
* H1 NET LOSS EUR 8.0 MILLION VERSUS LOSS EUR 8.2 MILLION
YEAR AGO
* H1 CURRENT OPERATING LOSS EUR 7.4 MILLION VERSUS LOSS EUR
7.3
MILLION YEAR AGO
Source text for Eikon: ID:nEQb9yDHSa
Further company coverage: AFME.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Carvolix SA
See all newsBrief: Affluent Medical/Artus: Achieves Clinical Objective Of Dry Pilot Study In First Two Patients
Brief: Affluent Medical Announces Successful First-In-Human Implantation Of Its Artificial Sphincter Artus For The Treatment Of Stress Urinary Incontinence
Brief: Affluent Medical Closes Bridge Of 3.5 Million Euros Via Capital Increase From Key Shareholders
Brief: Affluent Medical H1 Operating Loss EUR 7.4 Mln
Brief: Affluent Medical Announces Positive Clinical 1-Yr Results For Kalios